MovDisordV3, France, Analysis, bibRecord, 000384

The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease

Identifieur interne : 000384 ( France/Analysis ); précédent : 000383; suivant : 000385

The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease

Auteurs : Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0244412

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Etude double insu, Piribédil, Bromocriptine, Lévodopa, Stimulant dopaminergique.

English descriptors

KwdEn :
- Bromocriptine, Dopamine agonist, Double blind study, Levodopa, Nervous system diseases, Parkinson disease, Piribedil.

Abstract

Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non-ergot selective D₂/D₃ agonist with α₂ antagonist properties shown to be effective in the treatment of PD. This 12-month international, randomized, double-blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson Disease Rating Scale (UPDRS III, Items 18-31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow-up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12-month study duration was observed both in the piribedil and bromocriptine groups (-7.9 ± 9.7 points from baseline versus -8.0 ± 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long-term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long-term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD.

Affiliations:

Allemagne, Argentine, Belgique, Espagne, France, Italie, Portugal, Royaume-Uni
Angleterre, Midlands de l'Ouest
Birmingham, Créteil

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001B77
to stream PascalFrancis, to step Curation: 001144
to stream PascalFrancis, to step Checkpoint: 001869
to stream Main, to step Merge: 004964
to stream Main, to step Curation: 003623
to stream Main, to step Exploration: 003623
to stream France, to step Extraction: 000384

Links to Exploration step

Pascal:06-0244412

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease</title>
<author><name sortKey="Castro Caldas, Alexandre" sort="Castro Caldas, Alexandre" uniqKey="Castro Caldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Instituto de Ciências da Saùde, Universidade Católica Portuguesa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Lisboa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CHR de la Citadelle, Service de Neurologie</s1>
<s2>Liège</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Fleni, Instituto de Investigaciones Neurologicas Raul Carrera Montaneses</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Queen Elisabeth Hospital, Neurology Research</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Universvità degli Studi, Clinica Neurologica</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Hospital Mutua de Terrassa, Servicio de Neurologia</s1>
<s2>Terrassa</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Terrassa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Institat de Recherches Internationales Servier (IRIS)</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institat de Recherches Internationales Servier (IRIS)</wicri:noRegion>
<wicri:noRegion>Institat de Recherches Internationales Servier (IRIS)</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Service de Neurologie, Centre Hospitalier Universitaire H. Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0244412</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0244412 INIST</idno>
<idno type="RBID">Pascal:06-0244412</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B77</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001144</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001869</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Castro Caldas A:the:parkinson:control</idno>
<idno type="wicri:Area/Main/Merge">004964</idno>
<idno type="wicri:Area/Main/Curation">003623</idno>
<idno type="wicri:Area/Main/Exploration">003623</idno>
<idno type="wicri:Area/France/Extraction">000384</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease</title>
<author><name sortKey="Castro Caldas, Alexandre" sort="Castro Caldas, Alexandre" uniqKey="Castro Caldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Instituto de Ciências da Saùde, Universidade Católica Portuguesa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Lisboa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CHR de la Citadelle, Service de Neurologie</s1>
<s2>Liège</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Wiesbaden</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
<wicri:noRegion>Deutsche Klinik für Diagnostik</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Fleni, Instituto de Investigaciones Neurologicas Raul Carrera Montaneses</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Queen Elisabeth Hospital, Neurology Research</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Universvità degli Studi, Clinica Neurologica</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Hospital Mutua de Terrassa, Servicio de Neurologia</s1>
<s2>Terrassa</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Terrassa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Institat de Recherches Internationales Servier (IRIS)</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institat de Recherches Internationales Servier (IRIS)</wicri:noRegion>
<wicri:noRegion>Institat de Recherches Internationales Servier (IRIS)</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Service de Neurologie, Centre Hospitalier Universitaire H. Mondor</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Etude double insu</term>
<term>Piribédil</term>
<term>Bromocriptine</term>
<term>Lévodopa</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non-ergot selective D<sub>2</sub>
/D<sub>3</sub>
 agonist with α<sub>2</sub>
 antagonist properties shown to be effective in the treatment of PD. This 12-month international, randomized, double-blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson Disease Rating Scale (UPDRS III, Items 18-31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow-up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12-month study duration was observed both in the piribedil and bromocriptine groups (-7.9 ± 9.7 points from baseline versus -8.0 ± 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long-term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long-term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Argentine</li>
<li>Belgique</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Portugal</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
</region>
<settlement><li>Birmingham</li>
<li>Créteil</li>
</settlement>
</list>
<tree><country name="Portugal"><noRegion><name sortKey="Castro Caldas, Alexandre" sort="Castro Caldas, Alexandre" uniqKey="Castro Caldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name>
</noRegion>
</country>
<country name="Allemagne"><noRegion><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
</noRegion>
</country>
<country name="Argentine"><noRegion><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name>
</region>
</country>
<country name="Italie"><noRegion><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
</noRegion>
</country>
<country name="Espagne"><noRegion><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
</noRegion>
<name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000384 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000384 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:06-0244412
   |texte=   The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease

The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri